中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 36 Issue 8
Aug.  2020
Turn off MathJax
Article Contents

Value of microvascular invasion grade in predicting the early recurrence of hepatocellular carcinoma after radical hepatectomy

DOI: 10.3969/j.issn.1001-5256.2020.08.016
Research funding:

 

  • Published Date: 2020-08-20
  • Objective To investigate the value of microvascular invasion(MVI) grade versus TNM stage and Barcelona Clinic Liver Cancer(BCLC) stage in predicting the early recurrence of hepatocellular carcinoma(HCC) after radical hepatectomy and the clinical value of MVI grade through a retrospective analysis of the prognosis of patients after HCC surgery.Methods A total of 100 HCC patients who underwent radical hepatectomy in Department of Hepatobiliary Surgery,The Second Affiliated Hospital of Kunming Medical University,from December2015 to December 2017 were enrolled,and according to the results of the 2-year follow-up,these patients were divided into recurrence group with 49 patients and non-recurrence group with 51 patients.Laboratory markers and MVI grade were compared between the two groups,and MVI grade,TNM stage,and BCLC stage were compared in terms of their value in predicting 2-year recurrence-free survival(RFS) after surgery.The t-test was used for comparison of normally distributed continuous data between groups,and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between groups;the chi-square test was used for comparison of non-ranked data between two groups,and the Mann-Whitney U test was used for comparison of ranked data between groups;the Kruskal-Wallis H test was used for comparison between three groups,and the Bonferroni method was used for further comparison between two groups.The Kaplan-Meier method was used to plot survival curves,and the log-rank test was used for survival analysis.The consistency index calculated by RMS package was used to compare the predictive value of clinicopathological staging systems.Results Compared with the non-recurrence group,the recurrence group had significantly higher alpha-fetoprotein level(Z=0.099,P<0.05) and proportion of patients with MVI(Z=-2.651,P=0.008).After 2 years of follow-up,there were 47 patients in M0 group,34 in M1 group,and 19 in M2 group;18 patients in the M0 group(38.3%),16 in the M1 group(47.1%),and 15 in the M2 group(78.9%) experienced recurrence,and there was a significant difference in recurrence between the three groups(H=8.934,P=0.011);further comparison between two groups showed that the M2 group had a significantly higher number of patients with recurrence than the M0 group and the M1 group(P<0.05).The cumulative recurrence rate was 41.9% in the M0 + M1 group and 78.9% in the M2 group,and there was a significant difference between these two groups(χ2=11.445,P<0.001);the M2 group had a significantly lower 2-year RFS rate than the M0 + M1 group.As for BCLC stage,the cumulative recurrence rate was 36.2% in the patients with early-stage(stage 0 + stage 1) HCC and 66.7% in those with middle-and late-stage(stage 2 + stage 3) HCC,and there was a significant difference between the two groups(χ2=5.047,P=0.012);the middle-and late-stage group had a significantly lower 2-year RFS rate than the early-stage group.As for TNM stage,the cumulative recurrence rate was 24.5% in the patients with stage Ⅰ HCC and 72.5% in those with stage Ⅱ + Ⅲ HCC,and there was a significant difference between the two groups(χ2=17.223,P<0.001);the stage Ⅱ + Ⅲ group had a significantly lower 2-year RFS rate than the stage I group.TNM stage had the highest value in predicting 2-year RFS,while MVI and BCLC stage had a similar predictive value(consistency index:0.659 vs 0.598 vs 0.600).Conclusion Compared with MVI patients with no risk or low risk,patients with high-risk MVI have a significantly higher probability of early recurrence,and thus MVI may become an evaluation target for postoperative treatment.

     

  • loading
  • [1] DE’ANGELIS N,LANDI F,CARRA MC,et al. Managements of recurrent hepatocellular carcinoma after liver transplantation:A systematic review[J]. World J Gastroenterol,2015,21(39):11185-11198.
    [2] BRAY F,FERLAY J,SOERJOMATARAM I,et al. Global cancer statistics 2018:Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.
    [3] POON RT,FAN ST,TSANG FH,et al. Locoregional therapies for hepatocellular carcinoma:A critical review from the surgeon's perspective[J]. Ann Surg,2002,235(4):466-486.
    [4] WANG FS,FAN JG,ZHANG Z,et al. The global burden of liver disease:The major impact of China[J]. Hepatology,2014,60(6):2099-2108.
    [5] GARCEA G,ONG SL,MADDERN GJ. Predicting liver failure following major hepatectomy[J]. Dig Liver Dis,2009,41(11):798-806.
    [6] DONG JH,HUANG ZQ. Precise hepatectomy:A new concept of liver surgery in the 21st century[J]. Chin J Surg,2009,47(21):1601-1605.(in Chinese)董家鸿,黄志强.精准肝切除———21世纪肝脏外科新理念[J].中华外科杂志,2009,47(21):1601-1605.
    [7] CHEN K,YANG HJ,DENG XF,et al. Risk factors of primary hepatocellular carcinoma patients early term recurrence after radical resection and prediction model establishment[J]. Chin J Cancer Prev Treat,2018,25(5):48-52.(in Chinese)陈凯,杨洪吉,邓小凡,等.肝癌根治性切除术后早期复发危险因素分析及预测模型构建[J].中华肿瘤防治杂志,2018,25(5):48-52.
    [8] ROAYAIE S,BLUME IN,THUNG SN,et al. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma[J]. Gastroenterology,2009,137(3):850-855.
    [9] ZHANG XJ,WANG L. Clinical significance of microvascular invasion in the comprehensive diagnosis and treatment of hepatocellular carcinoma[J]. Chin J Dig Surg,2019,18(4):336-341.(in Chinese)张小晶,王琳.微血管侵犯在肝癌综合诊断与治疗中的临床意义[J].中华消化外科杂志,2019,18(4):336-341.
    [10] ZHANG XJ,LIU J,LIU K,et al. Effect of microvascular invasion on prognosis of patients with hepatocellular carcinoma after hepatectomy[J]. Chin J Dig Surg,2018,17(5):483-487.(in Chinese)张小晶,刘静,刘坤,等.微血管侵犯对肝癌肝切除术后预后的影响[J].中华消化外科杂志,2018,17(5):483-487.
    [11] Chinese Society of Liver Cancer,Chinese Anti-Cancer Association; Liver Cancer Study Group,Chinese Society of Hepatology,Chinese Medical Association; Chinese So-ciety of Pathology,Chinese Anti-Cancer Association,etal. Evidencebased practice guidelines for the standardized pathological diagnosis of primary liver cancer in China(2015 update)[J]. J Clin Hepatol,2015,31(6):833-839.(in Chinese)中国抗癌协会肝癌专业委员会,中华医学会肝病会分会肝癌学组,中国抗癌协会病理专业委员会,等.原发性肝癌规范化病理诊断指南(2015年版)[J].临床肝胆病杂志,2015,31(6):833-839.
    [12] National Health and Family Planning Commission of the People’s Republic of China. Diagnosis,management,and treatment of hepatocellular carcinoma[J]. J Clin Hepatol,2017,33(8):1419-1431.(in Chinese)中华人民共和国国家卫生和计划生育委员会.原发性肝癌诊疗规范(2017年版)[J].临床肝胆病杂志,2017,33(8):1419-1431.
    [13] CHUN YS,PAWLIK TM,VAUTHEY JN. 8th edition of the AJCC cancer staging manual:Pancreas and hepatobiliary cancers[J]. Ann Surg Oncol,2018,25(4):845-847.
    [14] RODRGUEZ-PERLVAREZ M,LUONG TV,ANDREANA L,et al. A systematic review of microvascular invasion in hepatocellular carcinoma:Diagnostic and prognostic variability[J].Ann Surg Oncol,2013,20(1):325-339.
    [15] WANG J,MA JL. Prognostic factors of liver cancer[J]. Chin J Pract Surg,2015,24(2):270-274.(in Chinese)汪晋,马金良.肝癌预后相关影响因素[J].中国普通外科杂志,2015,24(2):270-274.
    [16] FENG LH,DONG H,LAU WY,et al. Novel microvascular invasion-based prognostic nomograms to predict survival outcomes in patients after R0 resection for hepatocellular carcinoma[J]. J Cancer Res Clin Oncol,2017,143(2):293-303.
    [17] ZHAO H,CHEN C,FU X,et al. Prognostic value of a novel risk classification of microvascular invasion in patients with hepatocell ular carcinoma after resection[J]. Oncotarget,2017,8(3):5474-5486.
    [18] SUN Z,WANG ZN,ZHU Z,et al. Evaluation of the seventh edition of American Joint Committee on Cancer TNM staging system for gastric cancer:Results from a Chinese monoinstitutional study[J]. Ann Surg Oncol,2012,19(6):1918-1927.
    [19] JING JS,KANG W,ZHANG CZ,et al. Postoperative adjuvant transcatheter arterial chemoembolization after R0 hepatectomy improves outcomes of patients who have hepatocellular carcinoma with microvascular invasion[J]. Ann Surg Oncol,2016,23(4):1344-1351.
    [20] PENG ZW,CHEN SL,XIAO H,et al. Microvascular invasion as a predictor of response to treatment with sorafenib and transarterial chemoembolization for recurrent intermediatestage hepatocellular carcinoma[J]. Radiology,2019,292(1):237-247.
    [21] SHI FX,ZHOU Z,HUANG XZ,et al. Is anatomical resection necessary for early hepatocellular carcinoma? A single institution retrospective experience[J]. Future Oncol,2019,15(17):2041-2051.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (1476) PDF downloads(217) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return